Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Clinical trial NCT07326566 · RECRUITING

Trial details

NCT number: NCT07326566
Sponsor: Black Diamond Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Glioblastoma (GBM)Newly Diagnosed Glioblastoma GBM Glioblastoma Multiforme (GBM)Glioma Central Nervous System Diseases Brain Cancer

Start date: 2026-05-05
Primary completion: 2028-11-01
Enrollment: 162

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.